Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biopharmaceutical firm Spyryx Biosciences has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of its therapeutic peptides for cystic fibrosis (CF).
Subscribe to our email newsletter
In the CF lung, the epithelial sodium channels (ENaC) hyperabsorb sodium and water from the surface of the lung airway, this leads to dehydration of the mucus layers and reduced airway clearance.
Spyryx president and CEO John Taylor said: "We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to working closely with them as we advance our program toward clinical development."
The company is developing inhaled peptides, which are designed to potently degrade ENaC, blocking this absorption and returning airway fluid volumes to normal levels, with the goal of restoring proper mucociliary clearance.
According to the company, this therapeutic approach is independent of the genetic mutations that cause the disease and is expected to provide a treatment option to the entire CF patient population.
In preclinical models, the company’s compounds have also showed robust restoration of airway fluid volumes with a duration of action that may allow once-daily dosing in the clinic.